source
- FDA questions efficacy of Capricor's Duchenne muscular dystrophy cell therapy ahead of advisory committeeFDA reviewers have raised concerns about the efficacy of Capricor's cell therapy for Duchenne muscular dystrophy as the agency prepares for an advisory committee meeting. The agency said it could n…
- MapLight's schizophrenia drug fails primary endpoint in Phase 2, sending stock down over 60%MapLight Therapeutics saw its shares tumble more than 60% after a mid‑stage trial showed that its once‑daily schizophrenia candidate did not meet the primary efficacy endpoint, even though the over…